Diagnostic Reliability of OCT Biomarkers for iERM

Sponsor
Vienna Institute for Research in Ocular Surgery (Other)
Overall Status
Completed
CT.gov ID
NCT04997876
Collaborator
(none)
136
1
7.3
18.6

Study Details

Study Description

Brief Summary

Several optical coherence tomography (OCT) biomarkers with potential to influence postsurgical outcomes after vitrectomy with membrane peeling for idiopathic epiretinal membranes (iERM) have been described in single predictor analyses in the past. Aim of the study is to assess the reliability of diagnosis of OCT biomarkers and to calculate their impact on postsurgical visual acuity in a multiple regression analysis.

Condition or Disease Intervention/Treatment Phase
  • Other: Biomarker analysis

Detailed Description

Several optical coherence tomography (OCT) biomarkers with potential to influence postsurgical outcomes after vitrectomy with membrane peeling for idiopathic epiretinal membranes (iERM) have been described in single predictor analyses in the past. A recent multifactorial analysis outlined macular thickness and DRIL to be significant predictors for postsurgical visual acuity (Karasavviodou et al.). Nevertheless, reliability of diagnosing OCT biomarkes among patients with iERM was not yet assessed, to our knowledge. Aim of the study is to assess the reliability of diagnosis of OCT biomarkers and to calculate their impact on postsurgical visual acuity in a multiple regression analysis.

Study Design

Study Type:
Observational
Actual Enrollment :
136 participants
Observational Model:
Other
Time Perspective:
Retrospective
Official Title:
Diagnostic Reliability of OCT Biomarkers for Idiopathic Epiretinal Membranes
Actual Study Start Date :
Jan 11, 2021
Actual Primary Completion Date :
Aug 5, 2021
Actual Study Completion Date :
Aug 21, 2021

Arms and Interventions

Arm Intervention/Treatment
Study Group

Biomarkers from presurgical OCTs are diagnosed

Other: Biomarker analysis
Biomarkers from presurgical OCTs are assessed

Outcome Measures

Primary Outcome Measures

  1. reliability of diagnosing OCT biomarkers [1 week]

    The presence (yes/no) of following OCT biomarkers are diagnosed from preoperative OCTs: EIFL, DRIL, intraretinal cystoid changes, alterations of the ellipsoid zone, cotton ball sign, HR-foci, EMM-rips, and retinal contraction. Intra- and interobserver reliability is assessed from 2 different readers, and reliability of OCT biomarkers will be calculated with the Kuder Richardson 20 test, due to the dichtomic nature of outcomes.

Secondary Outcome Measures

  1. postsurgical best corrected visual acuity [3 months]

    best corrected visual acuity 3 months after surgery is used for regression analysis

  2. central macular thickness [5 minutes]

    presurgical central subfield thickness of the macula is assessed by the software of the OCT device. The subfield thickness with a diameter of 1mm will be selected.

Eligibility Criteria

Criteria

Ages Eligible for Study:
18 Years and Older
Sexes Eligible for Study:
All
Accepts Healthy Volunteers:
No
Inclusion Criteria:
    1. presence of an iERM,
    1. indication for membrane peeling, defined as significant loss of visual acuity and/or metamorphopsia due to the ERM,
    1. pseudophakia at the final visit at 3 months after surgery, and
    1. written informed consent for study participation.
Exclusion Criteria:
  • macular edema caused by conditions other than ERM were excluded from the study.

Contacts and Locations

Locations

Site City State Country Postal Code
1 VIROS at Hanusch-Hospital Vienna Vienna Austria 1140

Sponsors and Collaborators

  • Vienna Institute for Research in Ocular Surgery

Investigators

  • Principal Investigator: Oliver Findl, Prof., head of department

Study Documents (Full-Text)

None provided.

More Information

Publications

Responsible Party:
Prim. Prof. Dr. Oliver Findl, MBA, Prof., MD, MBA, Vienna Institute for Research in Ocular Surgery
ClinicalTrials.gov Identifier:
NCT04997876
Other Study ID Numbers:
  • biomarkers
First Posted:
Aug 10, 2021
Last Update Posted:
Aug 24, 2021
Last Verified:
Aug 1, 2021
Studies a U.S. FDA-regulated Drug Product:
No
Studies a U.S. FDA-regulated Device Product:
No
Additional relevant MeSH terms:

Study Results

No Results Posted as of Aug 24, 2021